Blood pressure reduction in hypertensive-diabetic rats by the somatostatin analog MK-678

  • Life Sci. 1989;45(3):267-74. doi: 10.1016/0024-3205(89)90260-9.
J Hartmann  1 ,  M Szemplinski ,  S L Chen ,  E Slater
Affiliations
  • 1. Merck Sharp & Dohme Research Laboratories, Department of Biochemical Endocrinology, Rahway, NJ 07065.
PMID: 2569653 DOI: 10.1016/0024-3205(89)90260-9
Abstract

A hypotensive effect of an orally-administered cyclopeptide somatostatin analog, MK-678, has been demonstrated in a hypertensive diabetic rat model. Sustained blood pressure reduction failed to occur when the drug was administered to the spontaneously hypertensive rat. The mechanism of hypotension appears independent of effects on a variety of Hormones including Insulin, glucagon, growth hormone, and components of the renin-angiotensin system including Renin activity, plasma angiotensin converting enzyme, and aldosterone.

Products